Recent Share Performance and Business Scale

Quest Diagnostics (DGX) has seen its stock decline about 1.4% over the past day and roughly 4% over the past week, while returns over the past month and past 3 months are close to flat.

Despite these short term moves, the company operates at considerable scale, with revenue of about $11.3b and net income of roughly $1.0b, and a market value near $21.6b based on the latest figures.

At a share price of US$195.0, Quest Diagnostics has seen short term share price returns soften recently. However, the year to date share price return of 12.2% and 5 year total shareholder return of 65.88% still point to a stock that has rewarded patient holders more than shorter term traders.

If you are considering how Quest Diagnostics fits into a broader healthcare theme, it can be useful to compare it with other opportunities that may benefit from similar trends, including 40 healthcare AI stocks.

With Quest Diagnostics showing steady longer term returns, annual revenue growth of 4.3% and net income growth of 9.9%, the key question is whether the current valuation leaves room for upside or if the market is already pricing in future growth.

Most Popular Narrative: 12.7% Undervalued

With Quest Diagnostics last closing at $195.0 against a widely followed fair value estimate of $223.44, the leading narrative frames the stock as modestly undervalued and emphasizes growth in higher value testing and data driven services.

Ongoing growth in advanced and preventive testing including cardiometabolic, autoimmune, brain health, oncology, and women's/reproductive diagnostics as well as robust demand from functional medicine and wellness-focused consumers, are driving higher test volumes and increasing test-per-requisition, which supports both revenue growth and margin expansion.

Read the complete narrative. Read the complete narrative.

Want to see what kind of revenue mix and margin profile that growth story points to, and how long it is expected to last? The narrative references a detailed path for earnings, future profitability, and the valuation multiple used to arrive at the $223.44 figure, without assuming anything extreme.

The fair value is based on specific expectations for steady top line expansion, a gradual lift in profit margins and a future P/E that sits below the sector average, all discounted at 7.13%. Result: Fair Value of $223.44 (UNDERVALUED).

However, the Quest Diagnostics narrative could be challenged if reimbursement cuts under PAMA or ongoing wage inflation squeeze margins more than current assumptions allow.

Next Steps

If the mixed signals around Quest Diagnostics leave you a bit undecided, take a moment to weigh both sides for yourself with the 4 key rewards and 1 important warning sign.

Looking for more Quest Diagnostics investment ideas?

If you like the way Quest Diagnostics fits your portfolio, do not stop there. Use the Simply Wall Street Screener to uncover more targeted opportunities across the market.

• Broaden your opportunity set by comparing Quest Diagnostics with other attractively priced companies using the 45 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that offer reliable cash returns through the 8 dividend fortresses.
• Dial down risk and focus on capital preservation by scanning companies highlighted in the 66 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.